Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 740

1.

Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials.

Hartmann CJ, Klistorner AI, Brandt AU, Schroeder K, Kolbe R, Cohn E, Goebels N, Guthoff R, Aktas O, Hartung HP, Albrecht P.

Clin Neurophysiol. 2014 Dec 27. pii: S1388-2457(14)00858-X. doi: 10.1016/j.clinph.2014.12.014. [Epub ahead of print] No abstract available.

PMID:
25613033
[PubMed - as supplied by publisher]
2.

Oligodendroglial maturation is dependent on intracellular protein shuttling.

Göttle P, Sabo JK, Heinen A, Venables G, Torres K, Tzekova N, Parras CM, Kremer D, Hartung HP, Cate HS, Küry P.

J Neurosci. 2015 Jan 21;35(3):906-19. doi: 10.1523/JNEUROSCI.1423-14.2015.

PMID:
25609610
[PubMed - in process]
3.

Subtle retinal pathology in amyotrophic lateral sclerosis.

Ringelstein M, Albrecht P, Südmeyer M, Harmel J, Müller AK, Keser N, Finis D, Ferrea S, Guthoff R, Schnitzler A, Hartung HP, Methner A, Aktas O.

Ann Clin Transl Neurol. 2014 Apr;1(4):290-7. doi: 10.1002/acn3.46. Epub 2014 Mar 11.

PMID:
25590041
[PubMed]
Free PMC Article
4.

Interferon-ß-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab.

Harmel J, Ringelstein M, Ingwersen J, Mathys C, Goebels N, Hartung HP, Jarius S, Aktas O.

BMC Neurol. 2014 Dec 17;14(1):247. [Epub ahead of print]

PMID:
25516429
[PubMed - as supplied by publisher]
Free PMC Article
5.

Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Miller-Little WA, Stuve O.

Expert Rev Clin Immunol. 2015 Jan;11(1):93-108. doi: 10.1586/1744666X.2015.992881. Epub 2014 Dec 15.

PMID:
25495182
[PubMed - in process]
6.

The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.

Kremer D, Förster M, Schichel T, Göttle P, Hartung HP, Perron H, Küry P.

Mult Scler. 2014 Dec 5. pii: 1352458514560926. [Epub ahead of print]

PMID:
25480862
[PubMed - as supplied by publisher]
7.

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.

Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, Wattjes MP, Svenningsson A, Olsson T, Hartung HP, Hermsen D, Tumani H, Adams O, Kieseier BC.

Mult Scler. 2014 Nov 12. pii: 1352458514556296. [Epub ahead of print]

PMID:
25392339
[PubMed - as supplied by publisher]
8.

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Pasquier RD, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH.

Mult Scler. 2014 Nov 12. pii: 1352458514554052. [Epub ahead of print]

PMID:
25392325
[PubMed - as supplied by publisher]
9.

Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.

Kaufman M, Cree BA, De Sèze J, Fox RJ, Gold R, Hartung HP, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, Ticho B, Duda P, Pace A, Campagnolo D.

J Neurol. 2014 Nov 9. [Epub ahead of print]

PMID:
25381458
[PubMed - as supplied by publisher]
10.

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.

Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung HP, Olsson T, Kieseier BC.

Neurology. 2014 Dec 2;83(23):2153-7. doi: 10.1212/WNL.0000000000001049. Epub 2014 Oct 31.

PMID:
25361781
[PubMed - in process]
11.

Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis.

Hartung HP, Aktas O, Boyko AN.

Mult Scler. 2014 Oct 24. pii: 1352458514549398. [Epub ahead of print] Review.

PMID:
25344374
[PubMed - as supplied by publisher]
12.

FoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies.

Meyer zu Hörste G, Cordes S, Mausberg AK, Zozulya AL, Wessig C, Sparwasser T, Mathys C, Wiendl H, Hartung HP, Kieseier BC.

PLoS One. 2014 Oct 6;9(10):e108756. doi: 10.1371/journal.pone.0108756. eCollection 2014.

PMID:
25286182
[PubMed - in process]
Free PMC Article
13.

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl C.

Ann Clin Transl Neurol. 2014 Aug;1(8):605-17. doi: 10.1002/acn3.91. Epub 2014 Aug 22.

PMID:
25285313
[PubMed]
Free PMC Article
14.

[Contribution of spinal cord biopsy to the differential diagnosis of longitudinal extensive transverse myelitis].

Ringelstein M, Aktas O, Harmel J, Prayer D, Jarius S, Wildemann B, Hartung HP, Salhofer-Polanyi S, Leutmezer F, Rommer PS.

Nervenarzt. 2014 Oct;85(10):1298-303. doi: 10.1007/s00115-014-4137-0. German.

PMID:
25148869
[PubMed - in process]
15.

Thymic epithelium determines a spontaneous chronic neuritis in Icam1(tm1Jcgr)NOD mice.

Meyer zu Horste G, Mausberg AK, Cordes S, El-Haddad H, Partke HJ, Leussink VI, Roden M, Martin S, Steinman L, Hartung HP, Kieseier BC.

J Immunol. 2014 Sep 15;193(6):2678-90. doi: 10.4049/jimmunol.1400367. Epub 2014 Aug 8.

PMID:
25108020
[PubMed - indexed for MEDLINE]
16.

IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, Lehmann HC.

J Neuroimmunol. 2014 Sep 15;274(1-2):225-9. doi: 10.1016/j.jneuroim.2014.06.007. Epub 2014 Jun 19.

PMID:
25002077
[PubMed - indexed for MEDLINE]
17.

Bacteria and their cell wall components uniformly co-activate interleukin-17-producing thymocytes.

Weber A, Zimmermann C, Kieseier BC, Hartung HP, Hofstetter HH.

Clin Exp Immunol. 2014 Dec;178(3):504-15. doi: 10.1111/cei.12414.

PMID:
24995465
[PubMed - indexed for MEDLINE]
18.

CD19 as a molecular target in CNS autoimmunity.

Stüve O, Warnke C, Deason K, Stangel M, Kieseier BC, Hartung HP, von Büdingen HC, Centonze D, Forsthuber TG, Knappertz V.

Acta Neuropathol. 2014 Aug;128(2):177-90. doi: 10.1007/s00401-014-1313-z. Epub 2014 Jul 4.

PMID:
24993505
[PubMed - in process]
Free PMC Article
19.

Alemtuzumab: the advantages and challenges of a novel therapy in MS.

Menge T, Stüve O, Kieseier BC, Hartung HP.

Neurology. 2014 Jul 1;83(1):87-97. doi: 10.1212/WNL.0000000000000540. Epub 2014 Jun 11. Review.

PMID:
24920854
[PubMed - indexed for MEDLINE]
20.

Interferon β-1a for multiple sclerosis: old drug, new clothes.

Hartung HP.

Lancet Neurol. 2014 Jul;13(7):638-9. doi: 10.1016/S1474-4422(14)70100-0. Epub 2014 May 28. No abstract available.

PMID:
24878062
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk